UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
---------------------
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. 2)*
Acadia Pharmaceuticals, Inc.
-----------------------------------------------------
(Name of Issuer)
Common Stock, $.0001 Par Value Per Share
-----------------------------------------------------
(Title of Class of Securities)
004225108
-----------------------------------
(CUSIP Number)
December 31, 2006
-----------------------------------------------------------
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
[_] Rule 13d-1(b)
[_] Rule 13d-1(c)
[X] Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
Page 1 of 17
CUSIP NO. 004225108 13G
________________________________________________________________________________
1. NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
OXFORD BIOSCIENCE PARTNERS IV L.P.
________________________________________________________________________________
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) [_]
(b) [_]
________________________________________________________________________________
3. SEC USE ONLY
________________________________________________________________________________
4. CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
________________________________________________________________________________
NUMBER OF 5. SOLE VOTING POWER
SHARES 0
_________________________________________________________________
BENEFICIALLY 6. SHARED VOTING POWER
OWNED BY 3,422,717
_________________________________________________________________
EACH 7. SOLE DISPOSITIVE POWER
REPORTING 0
_________________________________________________________________
PERSON 8. SHARED DISPOSITIVE POWER
WITH: 3,422,717
________________________________________________________________________________
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
3,422,717
________________________________________________________________________________
10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
[_]
________________________________________________________________________________
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
11.4%
________________________________________________________________________________
12. TYPE OF REPORTING PERSON*
PN
________________________________________________________________________________
Page 2 of 17
CUSIP NO. 004225108 13G
________________________________________________________________________________
1. NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
mRNA FUND II L.P.
________________________________________________________________________________
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) [_]
(b) [_]
________________________________________________________________________________
3. SEC USE ONLY
________________________________________________________________________________
4. CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
________________________________________________________________________________
NUMBER OF 5. SOLE VOTING POWER
SHARES 0
_________________________________________________________________
BENEFICIALLY 6. SHARED VOTING POWER
OWNED BY 3,422,717
_________________________________________________________________
EACH 7. SOLE DISPOSITIVE POWER
REPORTING 0
_________________________________________________________________
PERSON 8. SHARED DISPOSITIVE POWER
WITH: 3,422,717
________________________________________________________________________________
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
3,422,717
________________________________________________________________________________
10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
[_]
________________________________________________________________________________
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
11.4%
________________________________________________________________________________
12. TYPE OF REPORTING PERSON*
PN
________________________________________________________________________________
Page 3 of 17
CUSIP NO. 004225108 13G
________________________________________________________________________________
1. NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
OBP MANAGEMENT IV L.P.
________________________________________________________________________________
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) [_]
(b) [_]
________________________________________________________________________________
3. SEC USE ONLY
________________________________________________________________________________
4. CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
________________________________________________________________________________
NUMBER OF 5. SOLE VOTING POWER
SHARES 0
_________________________________________________________________
BENEFICIALLY 6. SHARED VOTING POWER
OWNED BY 3,422,717
_________________________________________________________________
EACH 7. SOLE DISPOSITIVE POWER
REPORTING 0
_________________________________________________________________
PERSON 8. SHARED DISPOSITIVE POWER
WITH: 3,422,717
________________________________________________________________________________
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
3,422,717
________________________________________________________________________________
10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
[_]
________________________________________________________________________________
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
11.4%
________________________________________________________________________________
12. TYPE OF REPORTING PERSON*
PN
________________________________________________________________________________
Page 4 of 17
CUSIP NO.004225108 13G
________________________________________________________________________________
1. NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
JEFFREY T. BARNES
________________________________________________________________________________
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) [_]
(b) [_]
________________________________________________________________________________
3. SEC USE ONLY
________________________________________________________________________________
4. CITIZENSHIP OR PLACE OF ORGANIZATION
United States
________________________________________________________________________________
NUMBER OF 5. SOLE VOTING POWER
SHARES 0
_________________________________________________________________
BENEFICIALLY 6. SHARED VOTING POWER
OWNED BY 3,422,717
_________________________________________________________________
EACH 7. SOLE DISPOSITIVE POWER
REPORTING 0
_________________________________________________________________
PERSON 8. SHARED DISPOSITIVE POWER
WITH: 3,422,717
________________________________________________________________________________
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
3,422,717
________________________________________________________________________________
10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
[_]
________________________________________________________________________________
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
11.4%
________________________________________________________________________________
12. TYPE OF REPORTING PERSON*
IN
________________________________________________________________________________
Page 5 of 17
CUSIP NO.004225108 13G
________________________________________________________________________________
1. NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
MARK P. CARTHY
________________________________________________________________________________
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) [_]
(b) [_]
________________________________________________________________________________
3. SEC USE ONLY
________________________________________________________________________________
4. CITIZENSHIP OR PLACE OF ORGANIZATION
United States
________________________________________________________________________________
NUMBER OF 5. SOLE VOTING POWER
SHARES 0
_________________________________________________________________
BENEFICIALLY 6. SHARED VOTING POWER
OWNED BY 3,422,717
_________________________________________________________________
EACH 7. SOLE DISPOSITIVE POWER
REPORTING 0
_________________________________________________________________
PERSON 8. SHARED DISPOSITIVE POWER
WITH: 3,422,717
________________________________________________________________________________
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
3,422,717
________________________________________________________________________________
10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
[_]
________________________________________________________________________________
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
11.4%
________________________________________________________________________________
12. TYPE OF REPORTING PERSON*
IN
________________________________________________________________________________
Page 6 of 17
CUSIP NO.004225108 13G
________________________________________________________________________________
1. NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
JONATHAN J. FLEMING
________________________________________________________________________________
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) [_]
(b) [_]
________________________________________________________________________________
3. SEC USE ONLY
________________________________________________________________________________
4. CITIZENSHIP OR PLACE OF ORGANIZATION
United States
________________________________________________________________________________
NUMBER OF 5. SOLE VOTING POWER
SHARES 0
_________________________________________________________________
BENEFICIALLY 6. SHARED VOTING POWER
OWNED BY 3,422,717
_________________________________________________________________
EACH 7. SOLE DISPOSITIVE POWER
REPORTING 0
_________________________________________________________________
PERSON 8. SHARED DISPOSITIVE POWER
WITH: 3,422,717
________________________________________________________________________________
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
3,422,717
________________________________________________________________________________
10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
[_]
________________________________________________________________________________
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
11.4%
________________________________________________________________________________
12. TYPE OF REPORTING PERSON*
IN
________________________________________________________________________________
Page 7 of 17
CUSIP NO.004225108 13G
________________________________________________________________________________
1. NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
MICHAEL E. LYTTON
________________________________________________________________________________
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) [_]
(b) [_]
________________________________________________________________________________
3. SEC USE ONLY
________________________________________________________________________________
4. CITIZENSHIP OR PLACE OF ORGANIZATION
United States
________________________________________________________________________________
NUMBER OF 5. SOLE VOTING POWER
SHARES 0
_________________________________________________________________
BENEFICIALLY 6. SHARED VOTING POWER
OWNED BY 3,422,717
_________________________________________________________________
EACH 7. SOLE DISPOSITIVE POWER
REPORTING 0
_________________________________________________________________
PERSON 8. SHARED DISPOSITIVE POWER
WITH: 3,422,717
________________________________________________________________________________
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
3,422,717
________________________________________________________________________________
10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
[_]
________________________________________________________________________________
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
11.4%
________________________________________________________________________________
12. TYPE OF REPORTING PERSON*
IN
________________________________________________________________________________
Page 8 of 17
CUSIP NO.004225108 13G
________________________________________________________________________________
1. NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
ALAN G. WALTON
________________________________________________________________________________
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) [_]
(b) [_]
________________________________________________________________________________
3. SEC USE ONLY
________________________________________________________________________________
4. CITIZENSHIP OR PLACE OF ORGANIZATION
United States
________________________________________________________________________________
NUMBER OF 5. SOLE VOTING POWER
SHARES 37,403
_________________________________________________________________
BENEFICIALLY 6. SHARED VOTING POWER
OWNED BY 3,422,717
_________________________________________________________________
EACH 7. SOLE DISPOSITIVE POWER
REPORTING 37,403
_________________________________________________________________
PERSON 8. SHARED DISPOSITIVE POWER
WITH: 3,422,717
________________________________________________________________________________
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
3,460,120
________________________________________________________________________________
10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
[_]
________________________________________________________________________________
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
11.6%
________________________________________________________________________________
12. TYPE OF REPORTING PERSON*
IN
________________________________________________________________________________
Page 9 of 17
CUSIP NO.004225108 13G
ITEM 1(a). NAME OF ISSUER: Acadia Pharmaceuticals, Inc. (the "Issuer")
ITEM 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
3911 Sorrento Valley Boulevard, San Diego, California, 92121
ITEM 2(a). NAMES OF PERSONS FILING: Oxford Bioscience Partners IV L.P.
("Oxford IV") and mRNA Fund II L.P. ("mRNA II") (collectively, the
"Funds"); OBP Management IV L.P. ("OBP IV"), which is the sole
general partner of Oxford IV and mRNA II; and Jeffrey T. Barnes
("Barnes"), Mark P. Carthy ("Carthy"), Jonathan J. Fleming
("Fleming"), Michael E. Lytton ("Lytton") and Alan G. Walton
("Walton") (collectively, the "General Partners"), who are the
general partners of OBP IV. The persons named in this paragraph
are referred to individually herein as a "Reporting Person" and
collectively as the "Reporting Persons."
ITEM 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
The address of the principal business office of Oxford IV, mRNA
II, OBP IV, Barnes, Carthy, Fleming and Lytton is 222 Berkeley
Street, Suite 1650, Boston, Massachusetts 02116. The address of
the principal business office of Walton is 315 Post Rd. West,
Westport, Connecticut 06880.
ITEM 2(c). CITIZENSHIP: The Funds and OBP IV are limited partnerships
organized under the laws of the State of Delaware. Each of the
Individual General Partners is a United States citizen.
ITEM 2(d). TITLE OF CLASS OF SECURITIES: Common Stock, $.0001 par value
("Common Stock").
ITEM 2(e). CUSIP NUMBER: 004225108.
ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SS.SS. 240.13d-1(b) OR
240.13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:
Not applicable.
ITEM 4. OWNERSHIP.
(a) Amount Beneficially Owned: Oxford IV is the record owner of
3,160,238 shares of Common Stock and immediately
exercisable warrants to purchase 236,500 shares of Common
Stock at an exercise price of $8.148 per share as of
December 31, 2006. mRNA II is the record owner of 25,979
shares of Common Stock as of December 31, 2006 (the shares
and warrants held of record by Oxford IV and mRNA II, the
"Record Shares"). As the sole general partner of Oxford IV
and mRNA II, OBP IV may be deemed to own the Records
Shares. As the individual general partners of OBP IV, each
of the General Partners may also be deemed to share the
power and direct the disposition and vote of the Record
Shares. In addition, as of December 31, 2006, Walton holds
the right to options to exercise 45,721 shares of Common
Stock of which 29,084 are immediately exercisable and
8,319 are exercisable within 60 days (the "Option Shares").
The remaining 8,318 are not exercisable within 60 days.
(b) Percent of Class: See Line 11 of the cover sheets. The
percentages set forth on the cover sheets for each
Reporting Person other than Walton are calculated based on
29,798,615 shares of Common Stock reported to be
outstanding by the Issuer in Form 10-Q as filed with the
Securities and Exchange Commission on November 6, 2006 for
the period ending September 30, 2006 (the "Reported
Shares"). Walton's percentage
Page 10 of 17
CUSIP NO. 004225108 13G
is calculated based on 29,836,018 shares, which includes
the Reported Shares and the Option Shares.
(c) Number of shares as to which such person has:
(i) Sole power to vote or to direct the vote: See Line 5 of
cover sheets.
(ii) Shared power to vote or to direct the vote: See Line 6
of cover sheets.
(iii) Sole power to dispose or to direct the disposition of:
See Line 7 of cover sheets.
(iv) Shared power to dispose or to direct the disposition
of: See Line 8 of cover sheets.
Each Reporting Person disclaims beneficial ownership of such
shares of Common Stock, except for the shares, if any, such
Reporting Person holds of record.
ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
Not applicable.
ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
Not applicable.
ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED
THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.
Not applicable.
ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
Not applicable. The Reporting Persons expressly disclaim
membership in a "group" as used in Rule 13d-5(b).
ITEM 9. NOTICE OF DISSOLUTION OF GROUP.
Not applicable.
ITEM 10. CERTIFICATION.
Not applicable. This statement on Schedule 13G is not filed
pursuant to Rule 13d-1(b) or Rule 13d-1(c).
Page 11 of 17
CUSIP NO.004225108 13G
SIGNATURE
After reasonable inquiry and to the best of its knowledge and belief,
each of the undersigned certifies that the information set forth in this
statement is true, complete and correct.
Date: February 14, 2007
OXFORD BIOSCIENCE PARTNERS IV L.P.
By: OBP MANAGEMENT IV L.P.
General Partner
By: *
--------------------------------
Jonathan J. Fleming
General Partner
mRNA FUND II L.P.
By: OBP MANAGEMENT IV L.P.
General Partner
By: *
--------------------------------
Jonathan J. Fleming
General Partner
OBP MANAGEMENT IV L.P.
By: *
---------------------------------
Jonathan J. Fleming
General Partner
*
-------------------------------------
Jeffery T. Barnes
*
-------------------------------------
Mark P. Carthy
*
-------------------------------------
Jonathan J. Fleming
*
-------------------------------------
Michael E. Lytton
Page 12 of 17
CUSIP NO.004225108 13G
*
-------------------------------------
Alan G. Walton
*By:/s/ Raymond Charest
----------------------------
Raymond Charest
As attorney-in-fact
This Schedule 13G was executed by Raymond Charest on behalf of the individuals
listed above pursuant to Powers of Attorney, copies of which are attached as
EXHIBIT 2.
Page 13 of 17
CUSIP NO.004225108 13G
EXHIBIT 1
AGREEMENT
Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934,
the undersigned hereby agree that only one statement containing the information
required by Schedule 13G need be filed with respect to the ownership by each of
the undersigned of shares of stock of Acadia Pharmaceuticals, Inc.
EXECUTED this 14 day of February, 2007.
OXFORD BIOSCIENCE PARTNERS IV L.P.
By: OBP MANAGEMENT IV L.P.
General Partner
By: *
--------------------------------
Jonathan J. Fleming
General Partner
mRNA FUND II L.P.
By: OBP MANAGEMENT IV L.P.
General Partner
By: *
--------------------------------
Jonathan J. Fleming
General Partner
OBP MANAGEMENT IV L.P.
By: *
---------------------------------
Jonathan J. Fleming
General Partner
*
-------------------------------------
Jeffery T. Barnes
*
-------------------------------------
Mark P. Carthy
*
-------------------------------------
Jonathan J. Fleming
Page 14 of 17
CUSIP NO. 004225108 13G
*
-------------------------------------
Michael E. Lytton
*
-------------------------------------
Alan G. Walton
*By: /s/ Raymond Charest
----------------------------
Raymond Charest
As attorney-in-fact
This Schedule 13G was executed by Raymond Charest on behalf of the individuals
listed above pursuant to Powers of Attorney, copies of which are attached as
EXHIBIT 2.
Page 15 of 17
CUSIP NO. 004225108 13G
EXHIBIT 2
POWER OF ATTORNEY
KNOW ALL MEN BY THESE PRESENTS, that each person whose signature
appears below hereby constitutes and appoints Raymond Charest, Alexia Pearsall
and Jonathan J. Fleming, and each of them, with full power to act without the
other, his true and lawful attorney-in-fact and agent, with full power of
substitution, for him and in his name, place and stead, in any and all
capacities (until revoked in writing) to sign any and all instruments,
certificates and documents required to be executed on behalf of himself as an
individual or in his capacity as a general partner or authorized signatory, as
the case may be, on behalf of any of Oxford Bioscience Partners IV L.P., mRNA II
L.P., or OBP Management IV L.P., pursuant to section 13 or 16 of the Securities
Exchange Act of 1934, as amended (the "Exchange Act"), and any and all
regulations promulgated thereunder and to file the same, with all exhibits
thereto, and any other documents in connection therewith, with the Securities
and Exchange Commission, and with any other entity when and if such is mandated
by the Exchange Act or by the By-laws of the National Association of Securities
Dealers, Inc., granting unto said attorney-in-fact and agent full power and
authority to do and perform each and every act and thing requisite and necessary
fully to all intents and purposes as he might or could do in person thereby
ratifying and confirming all that said attorney-in-fact and agent, or his
substitute or substitutes, may lawfully do or cause to be done by virtue hereof,
or may have done in connection with the matters described above.
IN WITNESS WHEREOF, this Power of Attorney has been signed as of the 8th day of
April, 2004.
OXFORD BIOSCIENCE PARTNERS IV L.P.
BY ITS GENERAL PARTNER, OBP MANAGEMENT IV L.P.
By: /s/ JONATHAN FLEMING
-----------------------------------------------
Name: Jonathan J. Fleming
Title: General Partner
mRNA FUND II L.P.
BY ITS GENERAL PARTNER, OBP MANAGEMENT IV L.P.
By: /s/ JONATHAN FLEMING
-----------------------------------------------
Name: Jonathan J. Fleming
Title: General Partner
OBP MANAGEMENT IV L.P.
By: /s/ JONATHAN FLEMING
-----------------------------------------------
Name: Jonathan J. Fleming
Title: General Partner
Page 16 of 17
CUSIP NO.004225108 13G
/s/ JEFFREY T. BARNES
---------------------------------------------------
Jeffrey T. Barnes
/s/ MARK P. CARTHY
---------------------------------------------------
Mark P. Carthy
/s/ JONATHAN J. FLEMING
---------------------------------------------------
Jonathan J. Fleming
/s/ MICHAEL E. LYTTON
---------------------------------------------------
Michael E. Lytton
/s/ ALAN G. WALTON
---------------------------------------------------
Alan G. Walton
Page 17 of 17